HeartBeam to Showcase FDA-Cleared Cardiac Technology at Major Investor Conferences
TL;DR
HeartBeam executives will showcase their FDA-cleared 3D ECG system at investor conferences, offering potential market advantages in portable cardiac monitoring technology.
The HeartBeam System uses a cable-free, credit card-sized device to collect 3D ECG signals from three non-coplanar directions for arrhythmia assessment.
HeartBeam's portable ECG technology enables cardiac monitoring outside medical facilities, improving access to care and early detection of heart conditions worldwide.
HeartBeam's credit card-sized device captures 3D heart signals, revolutionizing how arrhythmias are detected with portable technology cleared by the FDA.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) announced that CEO Robert Eno and CFO Timothy Cruickshank will present at three major investor conferences in September, including the MDB Investor Summit 2025, HRX Live 2025, and the H.C. Wainwright 27th Annual Global Investment Conference. The executives will provide updates on the company's commercialization progress and demonstrate the FDA-cleared HeartBeam System, a revolutionary medical device that represents a significant advancement in cardiac care technology.
The HeartBeam System is a cable-free, credit card-sized device capable of collecting 3D electrocardiogram (ECG) signals from three non-coplanar directions, which are then synthesized into a 12-lead ECG. This technology marks the first-ever cable-free device with this capability, enabling portable cardiac monitoring outside traditional medical facilities. The system's FDA clearance for arrhythmia assessment, granted in December 2024, positions HeartBeam at the forefront of remote cardiac health management innovation.
The company's platform technology is designed to deliver actionable heart intelligence wherever patients are located, allowing physicians to identify cardiac health trends and acute conditions without requiring hospital visits. This development is particularly important given the growing demand for remote healthcare solutions and the increasing prevalence of cardiac conditions worldwide. HeartBeam's technology could potentially reduce healthcare costs, improve patient outcomes, and increase accessibility to cardiac monitoring for underserved populations.
HeartBeam holds over 20 issued patents related to its technology enablement, providing strong intellectual property protection for its innovations. The company's 12-Lead ECG synthesis software is currently under FDA review, representing the next phase in the technology's regulatory approval process. Additional information about HeartBeam's developments is available through the company's newsroom at https://ibn.fm/BEAT.
The upcoming investor presentations provide an opportunity for the medical technology community and investors to assess HeartBeam's progress in bringing this transformative technology to market. The company's approach to cardiac care monitoring addresses critical gaps in current healthcare delivery, particularly in enabling early detection and continuous monitoring of cardiac conditions outside clinical settings. This technology has the potential to significantly impact how cardiac health is managed globally, making these investor conferences crucial for understanding the company's trajectory and the broader implications for the medical technology industry.
Curated from InvestorBrandNetwork (IBN)
